All In Biotech

Drug Trial Radar · NCT02752776

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Without Previous Exposure to Systemic Therapy.

Last checked: Nov 20, 2026Latest source record: Sep 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,660

Actual

Start

Mar 17, 2016

Primary completion

Mar 28, 2018

Study completion Mar 28, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

Conditions

  • Plaque Psoriasis

Interventions

  • SecukinumabDrug

    Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16Time frame: 16 weeks

Locations

215 sites in 17 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Seraing, Belgium

  • Novartis Investigative Site

    Geel, BEL, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Pilsen, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Ústí nad Labem, Czech Republic, Czechia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Tartu, Estonia

  • Novartis Investigative Site

    Angers, France

  • Novartis Investigative Site

    Antony, France

  • Novartis Investigative Site

    Argenteuil, France

  • Novartis Investigative Site

    Auxerre, France

  • Novartis Investigative Site

    Bayonne, France

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Boulogne-sur-Mer, France

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Cannes, France

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Grenoble, France

  • Novartis Investigative Site

    La Rochelle, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Martigues, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Nîmes, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Pringy, France

  • Novartis Investigative Site

    Quimper, France

  • Novartis Investigative Site

    Reims, France

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.